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Abstract
Regulation of gene expression is one of several roles proposed for the stress-induced
nucleotide diadenosine tetraphosphate (Ap4A). We have examined this directly by a com-
parative RNA-Seq analysis of KBM-7 chronic myelogenous leukemia cells and KBM-7 cells
in which the NUDT2 Ap4A hydrolase gene had been disrupted (NuKO cells), causing a 175-
fold increase in intracellular Ap4A. 6,288 differentially expressed genes were identified with
P < 0.05. Of these, 980 were up-regulated and 705 down-regulated in NuKO cells with a
fold-change 2. Ingenuity1 Pathway Analysis (IPA1) was used to assign these genes to
known canonical pathways and functional networks. Pathways associated with interferon
responses, pattern recognition receptors and inflammation scored highly in the down-regu-
lated set of genes while functions associated with MHC class II antigens were prominent
among the up-regulated genes, which otherwise showed little organization into major func-
tional gene sets. Tryptophan catabolism was also strongly down-regulated as were numer-
ous genes known to be involved in tumor promotion in other systems, with roles in the
epithelial-mesenchymal transition, proliferation, invasion and metastasis. Conversely,
some pro-apoptotic genes were up-regulated. Major upstream factors predicted by IPA1 for
gene down-regulation included NFκB, STAT1/2, IRF3/4 and SP1 but no major factors con-
trolling gene up-regulation were identified. Potential mechanisms for gene regulation medi-
ated by Ap4A and/or NUDT2 disruption include binding of Ap4A to the HINT1 co-repressor,
autocrine activation of purinoceptors by Ap4A, chromatin remodeling, effects of NUDT2 loss
on transcript stability, and inhibition of ATP-dependent regulatory factors such as protein
kinases by Ap4A. Existing evidence favors the last of these as the most probable mecha-
nism. Regardless, our results suggest that the NUDT2 protein could be a novel cancer che-
motherapeutic target, with its inhibition potentially exerting strong anti-tumor effects via
multiple pathways involving metastasis, invasion, immunosuppression and apoptosis.
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Introduction
Nudix hydrolases regulate the levels of a wide variety of canonical and modified nucleotides
and some non-nucleotide phosphorylated substrates as well as participating in essential pro-
cesses such as mRNA decapping [1, 2]. One of the best studied is mammalian NUDT2. This
enzyme has been isolated from many sources [3, 4] and its principal substrate is believed to be
diadenosine 50,5000-P1,P4-tetraphosphate (Ap4A). In animal cells, Ap4A can be synthesized by
most aminoacyl-tRNA synthetases, DNA ligases, firefly luciferase and acyl-CoA synthetases
while a further range of enzymes is able to do so in plants, fungi and bacteria [5–7]. Synthesis
usually involves transfer of AMP from an acyl-AMP or enzyme-AMP reaction intermediate to
an ATP acceptor. It can also be degraded by a number of enzymes in addition to NUDT2,
including FHIT [8], aprataxin [9] and non-specific phosphodiesterases [3]. However, NUDT2
is believed to be principally responsible for maintaining the low level of intracellular Ap4A
[10–12].
An increase in Ap4A resulting from activation of synthesis, inhibition of degradation or
both has been implicated in several intracellular processes. Genotoxic, thermal and other
stresses lead to increased Ap4A [13–17] and so Ap4A has been implicated in the regulation of
DNA replication after DNA damage and in promoting apoptosis [17–19]. Ap4A may also be
raised in response to external ligands and act as an intracellular second messenger [20–22]. It
also acts as an extracellular messenger through its interaction with a number of P2-type recep-
tors [23]. Ap4A is also a ligand for a number of proteins including a multiprotein complex con-
taining DNA polymerase-α [24, 25], protein kinases [26–28], uracil-DNA glycosylase [29],
protein chaperones [30], the HINT1 tumor suppressor [31], 50-nucleotidase II [32], CBS
domain proteins [33, 34] and CFIm25 [35], but in most cases the significance of this binding is
not clear. Of particular interest, however, is the possibility that Ap4A may act as a transcrip-
tional regulator. It has been suggested that an increased level of Ap4A induced in mast cells by
external factors activates the expression of a subset of genes controlled by the MITF and USF2
transcription factors by binding to and displacing the inhibitory HINT1 protein from these fac-
tors [10, 31, 36].
In order to determine whether transcriptional regulation by Ap4A is confined to relatively
few genes or is more widespread, we have analysed the transcriptome of a knockout derivative
of the KBM-7 chronic myeloid leukaemia (CML) cell line [37] in which the intracellular level
of Ap4A has been increased 175-fold by disruption of the NUDT2 gene (KBM-7-NuKO,
referred to hereafter as NuKO). These cells show profound changes in gene expression com-
pared to the parent KBM-7 cell line with a total of 6288 significantly differentially expressed
genes (DEGs) identified. Ingenuity1 Pathway Analysis was used to highlight the gene networks
and metabolic and signaling pathways affected, revealing down-regulation of interferon,
inflammatory and innate immune responses and up-regulation of processes involving MHC
class II antigens. In addition, many of the most strongly affected genes have roles in promoting
cancer metastasis and invasion, suggesting that NUDT2 may offer a novel, pleiotropic target
for cancer chemotherapy.
Materials and Methods
Cells
The KBM-7 reference clone B (product no. P00174E07) and the KBM-7-NuKO derivative
(P01289H04) in which the NUDT2 gene has been inactivated by retroviral gene-trap insertion
[38] were obtained from Haplogen and maintained at 37°C in 5% (v/v) CO2/air in Isocoves
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modified Eagle medium (IMEM, Sigma) supplemented with 10% (v/v) Foetal Bovine Serum
(Sigma), 2 mM L-glutamine (Sigma) and 100 μg mL -1 penicillin-streptomycin (Sigma).
Measurement of Ap4A and derivatives
The level of intracellular Ap4A in log phase KBM-7 and NuKO cells was determined as previ-
ously described using a sensitive luminometric assay with slight modifications for use with sus-
pension cells [17, 39]. Cells were harvested from suspension by centrifugation at 500 g for 5
min and used for nucleotide extraction. Ap4A was also measured in the growth medium super-
natant from these cells, which was filtered through a 0.2 μmMillipore filter, deproteinized with
10% TCA, then assayed as above. ADP-ribosylated derivatives of Ap4A (ADPR-Ap4A) were
separated by ion-exchange chromatography and identified and assayed as previously described
[17].
Growth inhibition assays
Cells (2 x 105) were seeded into 25 cm2 flasks containing 7 mL of growth medium. Chemical
agents were added as stated and cells grown for 96 h at 37°C after which cultures were centri-
fuged at 500 g for 5 min, cells resuspended in fresh medium, and counted using a haemocyt-
ometer. Average counts were normalized to the cell count of the untreated culture.
RNA-Seq analysis: cDNA library preparation and sequencing
Three independent samples of total RNA were prepared from both KBM-7 and NuKO cells.
RNA extraction was performed using a Qiagen RNeasy mini kit with QIAshredder, and the
quantity and quality determined using a Nanodrop and Agilent Bioanalyzer. For each of the six
samples, 10 μg of RNA was DNase-treated using an Ambion TURBO DNA-free™ kit and subse-
quently purified using AMPure XP beads. 2 μg of the DNase-treated total RNA was then sub-
jected to rRNA depletion using the Ribo-Zero Gold (Human/Mouse/Rat) kit and purified
again with Ampure XP beads. Successful depletion was assessed using a Qubit fluorometer and
Agilent 2100 Bioanalyzer and all of the depleted RNA was used for the RNA-Seq library prepa-
ration using the ScriptSeq v2 protocol. Following 15 cycles of amplification the libraries were
purified using Ampure XP beads. Each library was quantified using Qubit and the size distribu-
tion assessed using the Agilent 2100 Bioanalyzer. The final libraries were pooled in equimolar
amounts using the Qubit and Bioanalyzer data. The quantity and quality of each pool was
assessed with the Bioanalyzer and by qPCR using the KAPA Library Quantification kit for Illu-
mina platforms on a Roche LC480II Light Cycler according to manufacturer's instructions.
The template DNA was denatured according to the protocol described in the Illumina cBot
user guide and loaded at a concentration of 9 pM. Sequencing was carried out on one lane of
an Illumina HiSeq 2000 with version 3 chemistry generating 2 × 100 bp paired end reads. Qual-
ity control was maintained with a 1% PhiX spike-in.
Bioinformatic analysis of RNA-Seq data
Basecalling and de-multiplexing of indexed reads for each sample library was performed using
CASAVA 1.8.2 (Illumina). Raw fastq files were processed using Cutadapt 1.2.1 [40] with option
“-O 3” set to remove adapter sequences of 3 bp or more. Reads were further trimmed using
Sickle 1.200 to remove low quality bases and finally reads<10 bp were removed. The TopHat2
aligner version 2.0.10 [41] was used to align the trimmed R1-R2 read pairs to the human refer-
ence genome assembly GRCh38, which contains 64,253 genes. Default parameters were used
except for the library type option, which was set to “fr-secondstrand” for all samples as the kit
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used produced a second-strand library type (R1 is expected to map on the 50!30 strand and R2
on the 30!50 strand). Reads aligning to the reference in more than one position were discarded
and FKPM values (fragments per kilobase transcript per million reads mapped) calculated. Dif-
ferential gene expression analysis was conducted in the R environment using the edgeR pack-
age [42]. The count data were normalised across libraries using the Trimmed Mean M-values
(TMM) method in edgeR with default parameters. Tagwise dispersion parameters were esti-
mated and then used for log2FC (log2 Fold Change) estimation and testing in edgeR using the
Likelihood Ratio (LR test) [43]. P values associated with log2FC were adjusted for multiple test-
ing using the False Discovery Rate (FDR) approach [44]. Significant DEGs were defined as
those with an FDR-adjusted P value< 0.05. All original RNA-Seq data produced in this study
have been submitted to the EMBL-EBI ArrayExpress database under accession number
E-MTAB-4104.
RT-PCR analysis of selected genes
RNA extraction was performed using a Qiagen RNeasy mini kit with QIAshredder and cDNA
was synthesized using a Bioline Tetro cDNA synthesis kit, both according to the manufactur-
er’s instructions. The cDNA was then quantitated by PCR using Maxima SYBR Green master
mix (Thermo) and a StepOnePlus™ Real Time PCR system (Applied Biosystems). Primers were
obtained from Sigma and are listed in S1 Table. The 2-ΔΔCt method was used to determine rela-
tive transcript levels using the housekeeping GAPDH gene to normalize the data [45].
Pathway analysis
Genes showing 2-fold up- or down-regulation with an FDR-adjusted P value< 0.05 were
analyzed through the use of QIAGEN Ingenuity1 Pathway Analysis software (IPA1, QIA-
GEN, Redwood City, http://www.ingenuity.com) in order to assign them to different functional
networks. IPA1 uses the manually curated Ingenuity1 Knowledge Base, which contains infor-
mation from several gene and protein expression, interaction and annotation databases such as
IntACT, BIND and MiPs, as well as from the published literature [46]. We also used IPA to
identify functionally related genes that correspond to specific canonical pathways that were
most significant to the data set from a collection of 200 curated metabolic, cell-signaling cas-
cade and disease-associated pathways. Fisher’s exact test of independence was used to calculate
the probability that the association between the genes in the dataset and the canonical pathway
can be explained by chance alone. Finally, we used the IPA upstream regulator analysis to iden-
tify factors that may control the genes and pathways highlighted by network analysis to provide
testable hypotheses for gene regulation by Ap4A.
Results
Level of Ap4A in KBM-7-NuKO cells
The parent KBM-7 line used in this study contains the BCR-ABL1 gene fusion and potentially
inactivating mutations in TP53 and NOTCH1, but lacks the other common genetic aberrations
found in myeloid malignancies [38]. It expresses the majority of annotated proteins from a
wide range of signaling pathways, making it a suitable cell line for this study. The complete
absence of NUDT2 protein from the NuKO NUDT2 disruptant was confirmed by Western
blotting (Fig 1). The steady-state concentration of intracellular Ap4A in unstressed mammalian
cells is typically in the range 0.1–1.0 pmol/106 cells (0.05–0.5 μM), the exact amount being spe-
cies- and cell type-dependent [17, 47]. Log phase KBM-7 cells had a level of 0.21±0.02 (n = 3)
pmol/106 cells. However, the NuKO derivative had a 175-fold increased level of 36.9±0.3
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(n = 3) pmol/106 cells, providing the clearest evidence yet that Ap4A is an important NUDT2
substrate in vivo and that this enzyme plays an essential role in maintaining the low back-
ground level of Ap4A. Note that an Ap4A content of 1 pmol/10
6 cells equates roughly to an
intracellular concentration of 0.5 μM if uniformly distributed [17] so the level in NuKO cells
will be around 20 μM. Regarding whether this high level and the resulting changes in the cells
reported here are biologically relevant, we have previously measured up to 20 μMAp4A in
DNA repair-defective cells treated with mitomycin C [17] while a concentration as high as
775 μM has been reported in FCεR1-activated mast cells [31]. Chromatographic analysis of the
Ap4A from NuKO cells showed that about 35% was present in the form of ADP-ribosylated
derivatives (ADPR-Ap4A), mainly mono-ADPR-Ap4A (Fig 1). We have previously shown that
ADP-ribosylation of Ap4A by PARP1 and PARP2 in Chinese hamster EM9 cells and mouse
embryo fibroblasts occurs in response to DNA damage [17]; however, it appears that the high
level of Ap4A here is subject to constitutive ADP-ribosylation.
RNA-Seq and differential gene expression analysis
Ap4A has been reported to activate the transcription of subsets of genes controlled by the tran-
scription factors MITF and USF2 [31, 36]. In view of this, and to further explore the phenotype
of the NUDT2 knockout cells, we carried out a comparative analysis of the transcriptomes of
KBM-7 and NuKO cells by RNA-Seq to identify DEGs. An average of 46.1 million pairs of 100
bp paired-end reads per sample were generated that aligned to the reference human genome.
Alignment results are summarized in Table 1, showing the number and percentage of reads
mapped for each sample. Mapping percentages for the six samples were between 80.2 and
81.3%. 31,177 (48.5%) of the 64,253 reference genes had at least one read aligned while 33,076
genes had no read aligned from any of the six samples.
The difference in gene expression profiles between the two cell types is illustrated in the
Principal Component Analysis (PCA) plot of log2 gene expression data shown in Fig 2A. The
triplicate samples of each cell type are grouped well away from each other, indicating a high
degree of differential gene expression between them. Furthermore, the heatmap of the Pearson
Fig 1. Ion-exchange chromatography of Ap4A extracted from KBM-7-NuKO cells and (inset) western blot analysis of cell
extracts for the presence of NUDT2 protein. A nucleotide extract from NuKO cells was subjected to ion-exchange
chromatography and fractions assayed luminometrically for Ap4A as described in Materials and Methods. Inset: a sample of
recombinant NUDT2 and protein extracts of KBM-7 and KBM-7 NuKO cells were subjected to polyacrylamide gel electrophoresis
and subsequent nitrocellulose blots probed for the presence of NUDT2 with rabbit polyclonal anti-NUDT2 (Santa Cruz) followed by
detection with HRP-conjugated goat-anti-rabbit IgG and ECL visualization (ECL Select, GE Healthcare). Mouse β-actin was
detected with HRP-conjugated goat-anti-mouse IgG (Santa Cruz).
doi:10.1371/journal.pone.0154674.g001
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correlation coefficients in Fig 2B indicated that the expression profiles for the three samples
from the same cell type were much more closely correlated than samples from different cell
types, showing that the effect of NUDT2 knockout on gene expression was much stronger than
the influence of any technical or biological variations between samples. The heatmap also
shows a very high correlation (R>0.99) among samples from the same cell type. Thus, we can
conclude that the differential gene expression detected here is statistically very robust.
Of the 31,177 reads mapped (S2 Table) a total of 6,288 DEGs were identified with a P-value
(FDR-adjusted)< 0.05, of which 2,550 were up-regulated and 2,285 down-regulated with a
fold-change 1.2 (Fig 2C and S3 Table). The MA plot in Fig 2C shows a fairly symmetrical
distribution of up- and down-regulated genes at all levels of expression. Of these genes, 980
were up-regulated and 705 down-regulated with a fold-change 2. In both cases, 88% had
FPKM 0.3 for one or both of the WT and KO datasets. The 40 most strongly down- and up-
regulated annotated genes are shown in Tables 2 and 3 respectively. Note that many of these
genes had zero read counts for either the WT or KO datasets necessitating the addition of a
small zero-offset pseudocount by the edgeR software in order to calculate log2FC [42].
The RNA-Seq analysis was validated by performing real-time qRT-PCR on a selection of
genes representing various affected pathways (Fig 3). These results confirmed the direction of
regulation (up or down) for all genes studied. The magnitude of change was also similar for the
majority of genes, with a correlation coefficient of 0.83 between the two data sets (Fig 3, inset).
However, for some genes with a zero value of FPKM for one of the samples in the RNA-Seq
analysis, the use of the pseudocount method by edgeR to calculate a fold-change has led to a
significantly different value, e.g. GFRA1 and TNF. Nevertheless, the values calculated by edgeR
are used in the following discussions as they are available for all genes and are still a good rela-
tive indication of the change in expression. In order to show that the observed differential gene
expression correlates solely with increased Ap4A rather than the related ADPR-Ap4A deriva-
tives, qRT-PCR analysis was also performed with RNA extracted from NuKO cells grown in
the presence of 100 nM KU-0058948, a PARP1 and PARP2 inhibitor that prevents the synthe-
sis of ADPR-Ap4A species [17]. The results were very similar to those obtained in the absence
of KU-0058948 (Fig 3), showing that, for these genes at least, ADPR-Ap4A is not the cause of
the differential expression. The function of ADPR-Ap4A, if any, is still unclear.
Ingenuity1 Pathway Analysis
In order to place the gene expression data into a biological context, Ingenuity1 Pathway Anal-
ysis (IPA1) software was used to assign the DEGs to known canonical pathways and functional
Table 1. Number and percentage of readsmapped to the human reference genome.
Sample Reads to
aligna
Reads aligned to
genome
% of
alignment
Reads aligned in
pairs
% reads aligned in
pairs
% concordant
pairsb
KBM7.1 52,648,492 46,517,676 88.4 42,437,310 80.6 70.7
KBM7.2 48,836,484 43,222,156 88.5 39,472,258 80.8 70.5
KBM7.3 53,927,610 47,635,707 88.3 43,402,072 80.5 70.8
N2KO.1 63,959,114 56,363,684 88.1 51,618,308 80.7 71.6
N2KO.2 64,109,906 56,893,008 88.7 52,135,004 81.3 72.5
N2KO.3 59,263,006 52,123,251 88.0 47,532,894 80.2 70.5
aSum of R1 and R2 reads used in the alignment
bPercentage of read pairs both of whose reads aligned to the same chromosome.
All percentages were calculated based on the total number of reads to align.
doi:10.1371/journal.pone.0154674.t001
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networks in order to predict the biological functions of the transcriptional changes. For sim-
plicity, the initial analysis included only genes that were up- or down-regulated by 2-fold
(P< 0.05); however, where present in the resulting pathways and networks, genes up- or
down-regulated by 1.2 were also considered to be of potential interest as there is no biologi-
cal justification for a cut-off value of 2. It was found that the DEGs mapped to a large number
of pathways with a significant enrichment score (–log(P-value)) (S4 Table). Top ranked within
both up- and down-regulated gene sets were signaling pathways related to immunity and
inflammation. Pathways associated primarily with the innate immune response, such as activa-
tion of interferon regulatory factors (IRFs) by pattern recognition receptors (PRRs), and
inflammation were specifically enriched in the down-regulated set of genes while functions
associated with MHC class II antigens were specific for the set of up-regulated genes (Table 4).
The predominance of these pathways in the dataset may reflect the myeloid nature of the
KBM-7 cell line [37]. These pathways are discussed in detail below.
Fig 2. Principal component analysis (PCA), correlation analysis and MA plot of differential gene expression data. (A) PCA
plot of log2 gene expression data showing the 2nd and 3rd principal components. (B) Heatmap visualization of the Pearson
correlation coefficients of log2 gene expression between samples. The three samples from wild type KBM-7 cells are labeled
WT1-WT3 and those from the KBM-7-NuKO cells KO1-KO3. (C) MA plot showing the distribution of mean gene expression levels
(log2Counts Per Million mapped reads) against log2 Fold-Change (KO vsWT) for individual gene responses. Low expression genes
(log2CPM < −5) are colored orange. Significant differentially expressed genes (DEGs) are colored red; genes showing no change in
expression are colored black.
doi:10.1371/journal.pone.0154674.g002
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Table 2. The 40most strongly down-regulated genes in KBM7-NuKO cells.
Gene id Approved gene name Fold change FDR-P, KO vs WT1 FPKM WT2 FPKM KO2
GFRA1 GDNF family receptor alpha 1 3221.0 4.38E-298 2.548 0.000
ZNF660 zinc ﬁnger protein 660 1785.1 5.30E-174 2.094 0.000
DZIP1 DAZ interacting zinc ﬁnger protein 1 1364.6 0.00E+00 10.206 0.007
CROT carnitine O-octanoyltransferase 623.2 2.81E-60 0.958 0.000
EDIL3 EGF-like repeats and discoidin I-like domains 3 590.1 3.02E-68 0.785 0.000
PHACTR3 phosphatase and actin regulator 3 566.5 9.06E-65 0.711 0.000
NUDT2 nudix (NDP- linked moiety X)-type motif 2 545.0 1.03E-181 13.295 0.018
RAB42 RAB42, member RAS oncogene family 267.5 3.31E-31 0.936 0.000
MPZL2 myelin protein zero-like 2 260.3 0.00E+00 10.580 0.039
IFI44L interferon-induced protein 44-like 224.3 0.00E+00 5.862 0.026
GALM galactose mutarotase (aldose 1-epimerase) 203.4 1.84E-77 1.908 0.006
CRISP3 cysteine-rich secretory protein 3 161.1 9.10E-96 3.206 0.017
TP53TG1 TP53 target 1 (non-protein coding) 160.9 7.09E-19 1.194 0.000
MGMT O-6-methylguanine-DNA methyltransferase 157.9 1.56E-18 0.337 0.000
LUM lumican 142.9 9.87E-15 0.360 0.000
misc_RNA Y-RNA-like misc_RNA, chromosome 8 137.3 1.76E-15 9.261 0.000
BRINP3 bone morphogenetic/retinoic acid inducible protein 3 135.8 0.00E+00 32.885 0.243
NKX2-2 NK2 homeobox 2 125.3 8.96E-15 0.457 0.000
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 121.7 0.00E+00 8.783 0.071
GJA1 gap junction protein, alpha 1, 43kDa 120.4 3.14E-174 4.721 0.037
ABCC6 ATP-binding cassette, sub-family C, member 6 110.5 4.57E-13 0.111 0.000
GYPE glycophorin E (MNS blood group) 110.5 2.42E-12 0.418 0.000
ADGRL3 adhesion G protein-coupled receptor L3 109.0 6.96E-33 0.203 0.001
RAG2 recombination activating gene 2 107.5 4.59E-160 4.217 0.037
FIGN ﬁdgetin 87.7 1.97E-38 0.394 0.004
CPED1 cadherin-like and PC-esterase domain containing 1 87.1 4.13E-63 0.925 0.009
TMEM254 transmembrane protein 254 84.4 9.42E-90 2.303 0.025
GLDC glycine dehydrogenase (decarboxylating) 83.9 5.13E-10 0.136 0.000
JCHAIN joining chain of multimeric IgA and IgM 74.6 4.58E-27 1.160 0.011
CNTNAP5 contactin associated protein-like 5 72.1 3.90E-08 0.101 0.000
TM4SF1 transmembrane 4 L six family member 1 70.3 4.74E-24 0.502 0.005
CXCL10 chemokine (C-X-C motif) ligand 10 66.1 1.78E-181 30.704 0.463
KYNU kynureninase 64.5 1.46E-162 0.845 0.013
EVA1A eva-1 homolog A (C. elegans) 57.3 4.61E-30 0.929 0.014
CNTNAP4 contactin associated protein-like 4 54.8 2.13E-33 0.378 0.006
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 52.1 5.40E-19 0.246 0.003
TSPAN7 tetraspanin 7 51.4 7.66E-06 0.125 0.000
CD200 CD200 molecule 51.1 1.26E-98 2.669 0.051
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 49.4 4.24E-278 5.029 0.100
CXCL11 chemokine (C-X-C motif) ligand 11 47.1 4.54E-120 6.138 0.128
1False discovery rate-adjusted P-value
2Fragments per kilobase of transcript per million mapped reads, a measure of transcript abundance in KBM7 wild type (WT) and KBM7-NuKO (KO)
knockout cells
doi:10.1371/journal.pone.0154674.t002
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Table 3. The 40most strongly up-regulated genes in KBM7-NuKO cells.
Gene id Approved gene name Fold change FDR-P, KO vs WT1 FPKM WT2 FPKM KO2
LINC01224 long intergenic non-protein coding RNA 1224 1832.2 1.56E-149 0.000 10.839
ZNF483 zinc ﬁnger protein 483 1649.2 9.98E-143 0.000 2.201
OVOL1 ovo-like zinc ﬁnger 1 718.9 5.18E-50 0.000 1.434
FAM162B family with sequence similarity 162, member B 323.3 3.96E-30 0.000 2.382
NAP1L2 nucleosome assembly protein 1-like 2 280.2 9.86E-180 0.018 5.828
ZNF544 zinc ﬁnger protein 544 264.4 1.02E-171 0.007 1.991
SLC1A1 solute carrier family 1 110.2 1.06E-11 0.000 0.211
TACC2 transforming, acidic coiled-coil containing protein 2 107.6 8.60E-11 0.000 0.043
ATP10B ATPase, class V, type 10B 76.2 3.91E-08 0.000 0.051
EMC10 ER membrane protein complex subunit 10 67.6 1.74E-172 0.021 1.475
SGPP2 sphingosine-1-phosphate phosphatase 2 62.5 2.32E-41 0.013 0.992
GALNT5 polypeptide N-acetylgalactosaminyltransferase 5 59.8 1.73E-25 0.006 0.465
NHSL2 NHS-like 2 51.9 9.76E-06 0.000 0.098
ECT2L epithelial cell transforming 2 like 49.5 1.28E-05 0.000 0.080
SERPINB10 serpin peptidase inhibitor, clade B, member 10 47.1 2.28E-05 0.000 0.131
HLA-DOA major histocompatibility complex, class II, DOA 47.0 9.78E-05 0.000 0.088
FAM155A family with sequence similarity 155, member A 42.5 0.000444026 0.000 0.038
PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 42.2 7.28E-05 0.000 0.030
DNMT3L DNA (cytosine-5-)-methyltransferase 3-like 39.8 0.000129366 0.000 0.159
THY1 Thy-1 cell surface antigen 39.8 0.000129366 0.000 0.050
ABCA8 ATP-binding cassette, sub-family A (ABC1), 8 37.8 0.002009234 0.000 0.025
CYP26B1 cytochrome P450, family 26B, polypeptide 1 37.4 0.000229216 0.000 0.055
ANXA3 annexin A3 35.3 0.002276797 0.000 0.052
BASP1 brain abundant, membrane attached signal protein 1 35.2 0 4.294 151.21
MIXL1 Mix paired-like homeobox 35.0 0.000407311 0.000 0.129
SDC4 syndecan 4 34.8 1.39E-55 0.053 1.918
CELA1 chymotrypsin-like elastase family, member 1 32.9 0.009226334 0.000 0.259
TMEM176B transmembrane protein 176B 32.8 3.69E-09 0.011 0.502
SNX19 sorting nexin 19 32.8 0.011374951 0.000 0.030
NAV3 neuron navigator 3 32.6 0.00158859 0.000 0.022
LINC01124 long intergenic non-protein coding RNA 1124 32.6 0.001588576 0.000 0.115
HS6ST3 heparan sulfate 6-O-sulfotransferase 3 32.5 0.000722541 0.000 0.031
PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 32.5 0.000722541 0.000 0.037
LINC00925 long intergenic non-protein coding RNA 925 32.0 8.37E-20 0.006 0.233
AOC1 amine oxidase, copper containing 1 30.6 2.14E-58 0.059 1.881
C1orf204 chromosome 1 open reading frame 204 30.2 0.001942513 0.000 0.091
NDRG4 NDRG family member 4 30.1 0.00128289 0.000 0.023
NHS Nance-Horan syndrome 30.1 0.001597534 0.000 0.022
NIM1K NIM1 serine/threonine protein kinase 29.3 6.57E-17 0.012 0.429
A4GALT alpha 1,4-galactosyltransferase 29.1 3.48E-08 0.008 0.301
1False discovery rate-adjusted P-value
2Fragments per kilobase of transcript per million mapped reads, a measure of transcript abundance in KBM7 wild type (WT) and KBM7-NuKO (KO)
knockout cells
doi:10.1371/journal.pone.0154674.t003
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Interferon response and innate immunity. Interferons are important mediators of the
innate immune response, which provides an initial vital defence against invading pathogens
(viruses, bacteria, protozoa) following interaction of pathogen components with PRRs in vari-
ous cellular compartments. They can also inhibit cell proliferation, modulate the adaptive
immune response, and be pro- or anti-inflammatory, depending on context [48–51]. Submis-
sion of the set of 4,835 DEGs with fold change 1.2 to the Interferome database (v2.01) [52]
revealed a subset of at least 1,038 DEGs known to be regulated by Type I IFNs (IFNα and
IFNβ) in other systems. Roughly half of these overlapped with the set of 944 showing known
regulation by Type II IFNs (IFNγ). Some (56) also showed Type III (IFNλ) regulation with 15
of these potentially unique to Type III (S5 Table).
Fig 4 shows the IPA1 canonical pathway for activation of interferon receptors (IFNRs) by
Type I and Type II interferons, with examples of genes found to be differentially expressed in
this study highlighted. The majority of functions in this pathway were down-regulated, with
expression of IFNB being the most strongly affected (15-fold, S3 Table). The JAK-STAT signal-
ing pathways are central to the interferon response. In Type II interferon signaling, activated
STAT1 homodimers bind to the GAS (Interferon Gamma Activated Sequence) promoter and
induce gene expression while Type I signaling involves the combination of STAT1-STAT2 het-
erodimers with IRF9 (Interferon Response Factor 9) forming ISGF3 (Interferon Stimulated
Gene Factor), which then binds to the ISRE (Interferon-Stimulated Response Element) pro-
moter. STAT1, STAT2 and IRF9 were all down-regulated (1.4-, 1.8- and 3.7-fold respectively)
Fig 3. Validation of RNA-Seq data for differential gene expression by qRT-PCR. qRT-PCR analysis was performed on selected
RNAs from KBM-7 and NuKO cells in the presence and absence of 100 nM of the PARP inhibitor KU-0058948 using the primers listed in
S1 Table as described in Materials and Methods and the log2 fold-change in expression plotted beside those obtained by RNA-Seq
analysis. Inset: simple correlation plot of the log2 fold-changes in expression obtained by RNA-Seq (x-axis) and qRT-PCRwithout PARP
inhibitor (y-axis).
doi:10.1371/journal.pone.0154674.g003
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while the pathway suppressors SOCS1 and PTPN2 were up-regulated (1.2–1.4-fold). Though
individually slight, the combined effect of these changes could nevertheless be significant. The
increases in SOCS1 and PTPN2 also show that there is not just a general suppression of gene
expression but that negative feedback via these genes is preserved. Finally, several of the STAT-
controlled genes that are down-regulated are themselves activators of further IFN response
genes, e.g. IRF1, IRF7 and IRF9 (1.2-, 3.8- and 3.7-fold respectively).
The canonical pathway in Fig 5 highlights the roles of the three RIG-1-like helicase PRRs of
the innate immune response, RIG-1 (DDX58), MDA5 (IFIH1) and LGP2 (DHX58) in the acti-
vation of IFNB following stimulation by viral double-stranded RNAs and the feedback pro-
vided by IFNβ on the expression of these PRRs. All three receptor genes are down-regulated
(3.1-, 2.3- and 3.0-fold respectively) (S3 Table) in NuKO cells. In addition, IFITM2 and
Table 4. Major IPA1 pathways and functions involving differentially regulated genes.
Top Down-regulated Canonical Pathways P-value
Activation of IRF by cytosolic pattern recognition receptors 4.04E-09
IL-1 signalling 1.80E-07
Recognition of bacteria and viruses by pattern recognition receptors 5.32E-07
Altered T cell and B cell signalling in rheumatoid arthritis 1.29E-06
B cell development 6.06E-06
Top Upstream Regulators Predicted activation
IFNL1 Inhibited
IFNA2 Inhibited
IL1RN Activated
TCR
IFNG Inhibited
Top Diseases and Biofunctions P-value
Antimicrobial response 8.33E-11–1.21E-11
Inﬂammatory response 3.99E-03–1.21E-11
Dermatological diseases and conditions 3.32E-03–1.62E-10
Cancer 4.11E-03–6.54E-09
Infectious disease 3.32E-03–1.41E-08
Top Up-regulated Canonical Pathways P-value
Allograft rejection signaling 1.10E-08
OX40 signaling pathway 5.15E-08
B cell development 4.09E-07
Antigen presentation pathway 5.67E-07
Autoimmune thyroid disease signaling 2.03E-06
Top Upstream Regulators Predicted activation
SMC3 Activated
PDLIM2
EBI3 Activated
MYOC
NEUROG1
Top Diseases and Biofunctions P-value
Cancer 3.66E-02–9.72E-08
Gastrointestinal disease 3.66E-02–5.57E-06
Hepatic system disease 3.66E-02–9.11E-06
Endocrine system disorders 3.66E-02–4.62E-05
Metabolic disease 3.66E-02–4.62E-05
doi:10.1371/journal.pone.0154674.t004
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IFITM3, whose products restrict the entry of many viruses [53], and all four antiviral IFIT fam-
ily members that bind viral components (IFIT1, 2, 3 and 5) [54] are down-regulated between
1.6- and 6.8-fold. Other down-regulated anti-viral genes include PKR, GBP1 and TLR10 [55–
58] (S3 Table).
Cytokine signaling, inflammation and NF-κB. Interleukin-1 (IL-1) signaling is flagged
by IPA1 as a top down-regulated pathway (Table 4) with reduced expression of important
pro-inflammatory members of the IL-1 superfamily [59]. For example, the mRNAs for IL-1β,
its receptor IL-1R1 and accessory protein IL-1RAP are decreased 1.5-, 11.7- and 1.2-fold
respectively while IL-18, IL-18R1 and IL-18RAP are down 2.3-, 3.0- and 4.0-fold respectively.
Expression of pro-inflammatory IL32 is also reduced 5-fold, while the expression of Tumor
Necrosis Factor (TNF or TNFα), which can activate both Type I IFNs and the inflammatory
mediator NF-κB, is down-regulated 30-fold (S3 Table). The canonical pathway leading to tran-
scriptional activation by NF-κB through IL-1, TNFα and other ligands is shown in Fig 6. The
NF-κB complex is an important mediator of inflammatory and immune responses and
responds to PRRs and pro-inflammatory cytokines [60]. It can synergize with STAT signaling
with the increased induction of target genes resulting from coordinate binding of STATs and
NF-κB to GAS and NF-κB promoters. The p50 and p52 components of the NF-κB complex
and the RELB transactivator are all down-regulated as are many components of signaling path-
ways that lead to NF-κB activation.
Fig 4. Canonical pathway for Type I and Type II interferon signaling via cell surface IFNR receptors.Down-regulated genes are in
green, up-regulated genes in red. Color intensity corresponds to the fold change; bold borders highlight genes with >2-fold change in
expression. Lines correspond to physical interactions and arrows to functional relationships between proteins. Solid lines and arrows imply
direct relationships and dotted lines and arrows imply indirect relationships. Functional relationships include post-translational modifications,
transcription regulation, proteolysis or co-expression. Flat arrowheads indicate inhibition.
doi:10.1371/journal.pone.0154674.g004
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Fig 5. Canonical pathway for the role of RIG-1-like receptors in antiviral innate immunity. Explanation of
symbols as in Fig 4.
doi:10.1371/journal.pone.0154674.g005
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It is known that Type I IFNs and TNF can mutually suppress each other’s expression, and it
has been suggested that changes in the cross-regulation of these pathways might affect the bal-
ance between the potential destructive and protective roles of these cytokines in the pathogene-
sis of autoimmune inflammatory diseases such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) [61]. IPA1 identifies signaling in RA as a top-ranked affected
canonical pathway (Table 4) and the list of DEGs associated with RA and SLE are shown in S6
Table. Although the modest changes in expression in some other cytokine receptors could
potentially be pro-inflammatory (e.g. IL10RA and IL23R), the overall picture is one of the
Fig 6. Canonical pathway for transcriptional activation by NFκB Explanation of symbols as in Fig 4.
doi:10.1371/journal.pone.0154674.g006
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suppression of inflammation by elevated Ap4A, with the down-regulation of NF-κB signaling
featuring strongly.
Up-regulated canonical pathways and MHC class II antigens. KBM-7 cells can be
regarded as immature precursors to professional antigen-presenting cells such as macrophages
and dendritic cells and almost all of the top 20 up-regulated canonical pathways flagged by
IPA1 involve functions associated with the adaptive immune response, including antigen pre-
sentation, OX40 signaling, allograft rejection and B cell development (Table 4 and S4 Table).
However, it should be emphasized that this is largely because these pathways all involve one of
the most prominent up-regulated gene sets, the inducible MHC class II antigens (MHC-II).
MHC-II molecules are mainly concerned with the presentation of antigens derived from extra-
cellular pathogens resulting in CD4+ T helper cell priming and the production of antibodies by
B cells [62]. Almost all class II subtype genes show a significant increase in expression, with
some showing a large increase, e.g. HLA-DOA 47-fold andHLA-DPA1 12-fold. Thus, the
extent to which these canonical pathways can be regarded as up-regulated as a whole is open to
question.
Nevertheless, in addition to MHC-II, a number of other genes involved in promotion of
aspects of the adaptive immune response are up-regulated in NuKO cells. OX40 (CD134,
TNFRSF4) is a member of the TNF receptor superfamily expressed by activated T helper cells
and other cells and when engaged by the OX40L ligand promotes the clonal expansion of effec-
tor and memory T cells responding to an antigen [63]. It is up-regulated 5-fold. CD86 (up
2.2-fold) is expressed on antigen-presenting cells and interacts with T cell surface ligands. It is
crucial for effective T cell activation and survival [64] and several studies have shown that
down-regulation or blockade of CD86 can improve allograft survival [65]. FCER1G (up 8-fold)
encodes the γ chain (FcRγ) of the high affinity IgE receptor FCεR1 [66]. FcRγ is also a compo-
nent of several other Fc receptors and the T-cell receptor, which may explain its association by
IPA1 with several immune functions. Interestingly, activation of mast cells by aggregation of
FCεR1 with IgE-antigen complexes has been reported to promote synthesis of Ap4A by lysyl-
tRNA synthetase and the consequent transcriptional changes [10, 31, 36]. Up-regulation of
FCER1G might therefore provide a mechanism to potentiate and prolong Ap4A synthesis.
Together, these data suggest reinforcement of elements of the adaptive immune response by
elevated Ap4A. As far as KBM-7 cells are concerned, this may indicate that Ap4A is promoting
their differentiation from a blast-like phenotype to a more mature stage [67]. There are some
apparent exceptions, such as the down-regulation of the recombination activating genes RAG1
and RAG2 (down 4.4- and 107-fold respectively). The RAG proteins catalyze VDJ recombina-
tion and are essential for the generation of mature, functional T and B cells [68]. These genes
are moderately expressed in KBM-7 cells and can be highly expressed in other blast-phase
CML-derived cell lines, e.g. NALM-1 [69]. However, their relevance to immune function is in
lymphocytes, in which their expression is normally confined, and in that context they may not
be down-regulated by high Ap4A.
Tryptophan catabolism. Canonical pathway analysis also shows that a number of meta-
bolic pathways including tryptophan (Trp) catabolism, and consequently de novo NAD+ bio-
synthesis (derived from Trp [70]), are strongly associated with the set of down-regulated genes
(Fig 7 and S4 Table) while creatine phosphate biosynthesis, melatonin degradation (also a Trp
derivative) and NAD+ phosphorylation are associated with the set of up-regulated genes. The
strong down-regulation of both major pathways of Trp catabolism, particularly the key
enzymes kynureninase (KYNU, 65-fold), indoleamine 2,3-dioxygenase (IDO1, 19-fold) and
DOPA decarboxylase (Trp decarboxylase, DDC, 16-fold) is of particular note. Expression of the
rate-limiting IDO1 is induced in myeloid-lineage cells by IFNs, particularly Type II, and TNF
can act synergistically to increase IDO1 expression [71], so the observed down-regulation of
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these pathways in NuKO cells combined with the moderate up-regulation of the negative effec-
tors DAP12 (TYROBP) and BIN1, a tumor suppressor, (S3 Table) [72] would be expected to
reduce IDO1 expression substantially.
There is strong evidence that Trp catabolism and IDO1 expression in dendritic cells, which
have a myeloid lineage, are important for the suppression of T-cell responses and the promo-
tion of immune tolerance [73]. The reduction of extracellular Trp, the generation of metabo-
lites via the kynurenine pathway and the signaling function of tyrosine-phosphorylated IDO1
all contribute to immunosuppression and protection against autoimmune disease and allograft
rejection by inhibiting the proliferation of T cells and NK cells and promoting autophagy and
anergy [74, 75]. The strong down-regulation of Trp catabolism caused by elevated Ap4A would
therefore be expected to promote T-cell responses and suppress tolerance. This is consistent
with the up-regulation of adaptive immune functions in NuKO cells predicted by IPA1
(Table 4). Furthermore, overexpression of IMPACT, an inhibitor of the GCN2-kinase
(EIF2AK4) stress-signaling pathway that represses translation and proliferation in response to
amino acid starvation, protects T-cells from Trp depletion [76]. IMPACT is up-regulated
13-fold in NuKO cells (S3 Table) and this would contribute further to the promotion of T-cell
responses if reproduced in T cells.
Cancer. Introduction of Ap4A by cold shock into some cell lines has been reported to
induce cell cycle arrest and apoptosis [19, 77]. It has also been shown that the level of NUDT2
expression positively correlates with lower survival and increased lymph node metastases in
Fig 7. Topmetabolic canonical pathways associated with down-regulated (black) and up-regulated (grey) gene sets. The
dotted line represents the threshold above which there are statistically significantly more genes in a pathway than expected by
chance (-log(FDR-adjusted P-value) >1.3).
doi:10.1371/journal.pone.0154674.g007
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breast carcinoma [78]. This suggests that low Ap4A might promote and/or high Ap4A might
inhibit cancer progression. Given the multifactorial nature of the disease, it is not surprising
that IPA1 classifies 1,108 of the 1,685 DEGs with 2-fold change and P 0.05 as being
increased, decreased or affected (usually by mutation association) in cancer. So, to investigate
further whether the level of Ap4A might correlate with cancer cell proliferation, survival or
metastasis, we have further filtered this DEG set to exclude those with FPKM values< 0.3 for
both WT and KO samples to focus attention on the more abundant transcripts and avoid any
uncertainties about the biological impact of DEGs with low level expression. We then con-
ducted a literature search on the 40 most strongly up-regulated and down-regulated annotated
protein-coding genes satisfying these conditions (S7 Table). Existing experimental evidence
suggests that reduced expression of 14 of the top 40 down-regulated genes would lead to a sig-
nificant anti-cancer effect while reduced expression of only 2 might have a promotional effect.
A further 3 could be pro- or anti-cancer depending on cellular context. Of the top 40 up-regu-
lated genes, increased expression of 8 restricts cancer progression in other systems, while only
2 promote it and one could possibly do either (S7 Table). Thus, increased intracellular Ap4A
seems to be associated overall with a strong anti-cancer effect. A more detailed appraisal of
these genes follows. It is worth noting that the well-characterized FHIT tumor suppressor pro-
tein that binds both Ap3A and Ap4A [8, 79] is not expressed in KBM-7 cells, probably as a
result of gene deletion [38].
Several genes showing a high degree of differential expression have been associated in other
cell systems with the epithelial-mesenchymal transition (EMT)—the loss of cell-cell adhesion
that initiates metastasis—and the reverse process, mesenchymal-epithelial transition (MET),
which stabilizes and integrates the cancer cells into tissues:
1. GFRA1 encodes a receptor for glial cell line-derived neurotrophic factor (GDNF) and is
classified by edgeR as the most strongly down-regulated gene in the dataset (3221-fold). The
proliferation of prostate cancer cells and their resistance to genotoxic treatment correlate
directly with the level of GFRA1 expression [80]. It is also up-regulated in breast carcinoma
[81] while GFRA1 released by cells can promote cancer cell migration and invasion [82].
2. Expression of the transcription factors OVOL1 and OVOL2 in mesenchymal prostate cancer
and poorly differentiated breast cancer cells induces MET and so inhibits their metastatic
potential [83]. It has been proposed that the EMT/MET balance is regulated by the ratio of
OVOL1/2 (promote MET) to ZEB1/2 (promote EMT) expression. OVOL1 is up-regulated
719-fold in NuKO cells (although OVOL2 expression is decreased 8-fold) while ZEB1 and
ZEB2 are slightly down 1.4- and 1.2-fold respectively.
3. The secreted glycoprotein EDIL3 has recently been identified as a novel inducer of EMT in
hepatocellular carcinoma. It promotes cell migration, invasion and angiogenesis [84]. It is
also up-regulated in oral squamous cell carcinoma [85] but is down-regulated 590-fold in
NuKO cells.
4. The mRNA binding protein IGF2BP1 promotes EMT while its knockdown reduces cell
migration in various mesenchymal-like tumor cells [86]. It is down 122-fold.
5. GJA-1 was recently characterized as a key gene for cervical cancer invasion and metastasis
[87] and is down 120-fold in NuKO cells.
6. The transmembrane protein TM4SF1 is overexpressed in many cancers and in the tumor
vascular endothelium [88] with its level correlating with poor prognosis in glioblastoma
[89]. Its down-regulation by an endogenous miRNA in prostate cancer cells inhibited
migration and invasion [90]. It is down 70-fold.
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7. BRINP3 overexpression in pituitary gonadotrope cells promotes proliferation, migration,
and invasion [91]. It is down 136-fold.
8. MPZL2 expression is significantly decreased in breast carcinoma cells growth-arrested by
siRNA knockdown of the migration and invasion regulatory PACE4 proprotein convertase
[92]. Its expression is reduced 260-fold in NuKO cells.
9. The RAC1-activating guanine nucleotide exchange factor PREX2, which is frequently
mutated in cancer and which promotes migration and invasion of various neoplasias [93,
94] is down 44-fold.
10. High expression of the HSP40 family member DNAJC12 has been found to correlate with
colorectal tumor progression and invasion and with a poor response to neoadjuvant con-
current chemoradiotherapy [95]. It is down-regulated 41-fold in NuKO cells.
11. Down-regulation of the transcription factor FOXD3 promotes an EMT phenotype in
breast cancer cells, causing proliferation and invasion both in vivo and in vitro while over-
expression inhibits this phenotype [96, 97]. Similar results have been found with other can-
cers [98, 99]. It is up-regulated 16-fold in NuKO cells.
12. Overexpression of NKD2, a negative regulator of Wnt signaling, in metastatic osteosar-
coma and breast carcinoma significantly reduces tumor growth and metastasis in vivo and
decreases cell proliferation, migration and invasion in vitro, while down-regulation has the
opposite effect [100, 101]. It is up-regulated 19-fold.
13. The leukemia inhibitory factor receptor LIFR has been shown to act as a suppressor of
metastasis in hepatocellular carcinoma [102]. Increased LIFR activity has also been corre-
lated with a reduction in the pool of breast cancer stem cells [103]. It is up-regulated
11-fold.
Several other prominent DEGs are known to affect growth and apoptosis in other systems.
The Wilms’ tumor transcriptional regulator WT1 can exhibit both oncogenic and tumor sup-
pressor activities depending on its association with specific co-regulators [104, 105]. For exam-
ple, the co-repressor BASP1 interacts with WT1 in a complex with PHB and BRG1 to favor
growth arrest and the induction of apoptosis over proliferation [106]. All these genes are well
expressed in KBM-7 cells, with BASP1 exhibiting 35-fold up-regulation in NuKO cells. Up-reg-
ulation of IFI44L is associated with melanoma and prostate cancer [107, 108] while overexpres-
sion of NKX2-2 is associated with Ewing’s sarcoma and fibromatosis [109]. They are down
224- and 125-fold respectively in NuKO cells. The homeobox transcription factor NKX3-1 is a
prostate tumor suppressor [110] and its expression is increased 13-fold in NuKO cells. Overex-
pression of the coiled coil domain protein CCDC68 decreased proliferation and tumorigenicity
of pancreatic ductal adenocarcinoma cells while allelic loss was found in about half the tumors
examined [111]. It has also been identified as a possible tumor suppressor in colorectal cancer
[112] and is up-regulated 11-fold in NuKO cells. Even genes with a more modest change in
expression could have a profound anti-cancer effect; for example, Interferon Regulatory Factor
4 (IRF4), an important NF-κB-activated regulator of immune system development and the
innate immune response [113], also plays an essential role in many lymphoid malignancies,
and knockdown of its expression by only 50% is lethal to multiple myeloma cells [114, 115]. It
is down-regulated 7-fold in NuKO cells.
Mixed results have been reported for a few of these DEGs in other contexts. For example,
high expression of the cysteine-rich secretory protein CRISP3 (down 130-fold in NuKO cells)
has been found in certain subtypes of prostate cancer [116] but down-regulation has been
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associated with oral squamous cell carcinoma [117]. A similar pattern has been found for the
JCHAIN component of IgA and IgM (down 75-fold), which is up-regulated in prostate [108]
but down-regulated in colorectal cancer [118]. The chemokine CXCL10 is another factor with
both tumor-promoting and anti-tumor effects, the latter largely through its immunogenic
action. It is overexpressed up to 40-fold in most types of cancer and can promote tumor cell
growth and metastasis [119] but is down 66-fold in NuKO cells. Mixed results have also been
reported for the Ig superfamily protein CD200 and the transmembrane co-receptor syndecan-
4 (SDC4), with both pro- and anti-cancer roles suggested in different situations [120–122].
They are down 51- and up 35-fold in NuKO cells respectively.
The change in expression of a small number of genes in NuKO cells could potentially pro-
mote cancer. For example, reduced expression of early B-cell factor 1 (EBF1) has been found in
Hodgkin lymphoma and appears to contribute to the loss of B-cell phenotype and consequent
malignancy [123]. There is also evidence for a tumor suppressor role in mouse leukemia [124].
It is down-regulated 38-fold. Expression of the TNF family member CD70 is normally
restricted to activated T and B-cells but it is activated in a wide variety of tumors where it pro-
motes tumor cell expansion and survival [125]. It is up-regulated 17-fold. Finally, type II trans-
glutaminase (TGM2) is up-regulated 10-fold in NuKO cells and may have an important role in
maintaining survival, invasion and the metastatic behavior of a variety of tumors and cancer
stem cells [126] while sphingosine-1-phosphate phosphatase 2 (SGPP2, up 63-fold) may be a
target for the tumor suppressor miRNA-31 [127].
If the above set of prominent DEGs were expressed and responded in the same way to
increased Ap4A in carcinomas, the overwhelming net effect could be the strong suppression of
tumor growth and, particularly, metastasis. Furthermore, as indicated previously, IDO1 and
several other enzymes of Trp catabolism are strongly down-regulated in NuKO cells. Increased
IDO1 expression is a characteristic of many cancer cells and assists them in avoiding clearance
by the immune system, with the level of expression often correlating with poor prognosis [72,
128] and so inhibitors of IDO1 have been considered as novel immunotherapeutic adjuvants to
conventional anti-cancer drugs [129, 130].
Taken together, there seems to be sufficient evidence to support NUDT2 as a novel chemo-
therapeutic target that could conceivably exert an anti-cancer effect via multiple pathways
involving apoptosis, metastasis, invasion and immunosuppression. One additional benefit of
targeting NUDT2 could be the 158-fold down-regulation of O6-methylguanine-DNA methyl-
transferase (MGMT). The MGMT protein dealkylates toxic and mutagenic O6-alkylguanine
lesions in DNA exposed to alkylating agents [131] and its reduced expression in NuKO cells
renders them much more sensitive to growth inhibition by methylmethane sulfonate (MMS),
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and N-methylnitrosourea (MNU) (Fig 8).
While down-regulation by high Ap4A would in theory promote the carcinogenic effect of envi-
ronmental alkylating agents, it would also render cancer cells more sensitive to alkylation ther-
apies such as temozolomide, a common treatment for glioblastoma and astrocytoma. MGMT
status is an important determinant of the success of these therapies [132]. This sensitivity to
methylating agents also provides good phenotypic confirmation of the transcriptomic data.
IPA1 prediction of upstream regulatory factors
IPA1 prediction of key upstream regulators for the DEGs suggests numerous factors control-
ling large sets of down-regulated genes with fewer factors controlling small groups of up-regu-
lated genes. Of the top 100 most significant potential regulators, 97 are proposed to contribute
to gene down-regulation (S8 Table) although the total number of genes that are up- and down-
regulated is similar. The inter-relationships between the top-ranked transcription factors
implicated in gene down-regulation and their major identified targets are shown in Fig 9. The
functions of several of these have already been described. In addition, CNOT7 (hCAF1) is a
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STAT1-binding negative regulator of Type I and Type II IFN signalling [133], while the tran-
scription factor IRF3 is an important responder to PRR activation (Fig 5) and co-operates with
NF-κB and IRF7 in the transcription of IRF3- and NF-κB-dependent genes [113]. SP1 controls
the transcription of multiple genes, many of which have been described as promoting the ‘hall-
marks’ of cancer: proliferation, independence from growth signals, avoidance of apoptosis and
immune destruction, invasion and metastasis, and angiogenesis. It is overexpressed in many
tumors, making it a target for chemotherapy [134, 135].
Control of up-regulated genes appears to be less integrated with different factors potentially
regulating small subsets of genes (S8 Table). Furthermore, of the top five listed regulators
(SMC3, PDLIM2, EBI3,MYOC and NEUROG1, Table 4), little or no expression of EBI3,
Fig 8. Growth inhibition curves for cells in the presence of (A) methylmethane sulfonate (MMS), (B)N-
methyl-N'-nitro-N-nitrosoguanidine (MNNG) and (C)N-methylnitrosourea (MNU).Growth of KBM-7
(open symbols) and KBM-7-NuKO (closed symbols) cells was assessed as described in Materials and
Methods. Data are presented as means ± SEM of the results obtained from three independent experiments.
When no error bar is shown, the error is smaller than the symbol. Statistical significance was assessed by
Student’s two-tailed t-test; *P < 0.05, **P < 0.01, ***P < 0.001 versusWT control.
doi:10.1371/journal.pone.0154674.g008
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MYOC and NEUROG1 was detected so their significance is hard to determine. In the case of
MHC-II genes, SMC3, a subunit of the cohesin protein complex, was identified as a possible
regulator. Cohesin co-operates with MHC-II specific transcription factors RFX5 and CIITA
(up 1.3-fold) to activate MHC-II expression [136]. SMC3 has an ATP-binding domain but
Fig 9. The top-ranked upstream transcription factors (in centre) suggested by IPA1 for the set of down-regulated genes (outer circle). The top
two-ranked cytokines, IFNA2 and IFNL1 are also included. Genes with >1.2 fold down-regulation are in green; those with >1.2-fold up-regulation are in red.
Color intensity corresponds to the fold change. Genes corresponding to immediate downstream targets of IRFs are enlarged with blue borders and
connections.
doi:10.1371/journal.pone.0154674.g009
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whether cohesin binding to MHC-II transcriptional insulators could be promoted by Ap4A is
unknown. The ubiquitin E3 ligase PDLIM2 (SLIM) is predicted by IPA1 to both up-regulate
and down-regulate different sets of genes (S8 Table). This prediction appears to be based
largely on the results of one previous investigation into PDLIM2-modulated gene expression in
DU145 prostate carcinoma cells [137] and the direction of expression change of about half the
genes in that study is different from that in ours. Given that the z-scores for the predictions are
both below the significance threshold of 2<z<-2, the reliability of this prediction is perhaps
questionable. Nevertheless, PDLIM2 suppression is known to alter the stability of several of the
transcription factor families implicated here in the down-regulated responses in NuKO cells
including NFκB, IRFs, STATs, JUN and AP-1, and also to promote reversal of the EMT pheno-
type [137]. Although the level of PDLIM2 expression in KBM-7 cells was not significantly
affected by NUDT2 knockout (S2 Table), its activity may have been altered as a secondary effect
of some other change e.g. to a protein kinase. Overall, though, there is no clear upstream pat-
tern of regulation for the sets of up-regulated genes.
Possible direct targets for Ap4A-mediated gene regulation
While IPA1may have identified potential upstream regulatory factors for some of the
observed changes in gene expression, the question still remains as to how the elevated level of
Ap4A impacts on these and other factors to promote these changes. A number of possibilities
can be considered.
HINT1. This study was initiated by the suggestion of Razin and co-workers that direct
activation of MITF and USF2 transcription complexes in mast-related cells occurred by Ap4A-
mediated displacement of the HINT1 co-repressor. For example, mast cell protease rMCP-6
(TPSB2), c-Kit (KIT), granzyme B (GZMB) and tryptophan hydroxylase (TPH1) were all up-
regulated in RBL cells either after direct introduction of Ap4A, after activation by IgE and anti-
gen, or after increasing Ap4A by siRNA knockdown of NUDT2 [10, 31]. However, IPA
1 did
not identify MITF (up 1.7-fold), USF2 or HINT1 (down 1.3-fold) as potential regulators in our
study. Furthermore, TPSB2 was up 3.2-fold but KIT was down 2.3-fold and TPH1 unaffected
(S2 and S3 Tables). No data were retrieved for GZMB. The USF2-responsive genes TGFB2,
SHP (NR0B2), TERT and TSP-1 (THBS1) were also shown to be up-regulated by Ap4A in RBL
cells [36]. In our study, USF2 expression was unchanged by NUDT2 knockout as was the very
low-level expression of TGFB2, TERT and THBS (S2 Table). No data were obtained for NR0B2.
Elevated Ap4A was also found to activate the MITF-dependent transcription of myosin light
chain 1a (MYL4) in cardiomyocytes [10], but this gene is not expressed in KBM-7 cells. From a
list of 113 genes shown to be up-regulated by MITF in melanoma [138], 23 were up- and 20
down-regulated in NuKO cells, which would suggest that Ap4A-mediated MITF or USF2 acti-
vation is not prominent in our data.
Other genes repressed by HINT1 through its interaction with MITF, USF2 or the WNT/β-
catenin complex include cyclin D1 (CCND1), BCL2, BIRC5,MET,MYC, FRA1, TGFB, HIF1A,
PAI-1 (SERPINE1) and AXIN2 [139–141]. Of these, BCL2,MYC and AXIN2 were slightly up-
regulated 1.3-, 1.3- and 2.4-fold while CCND1 was down-regulated 6.2-fold. Loss of HINT1 has
also been reported to reduce the expression of p21WAF1/CIP1 (CDKN1A), GADD45A,
GADD153 and TP53INP1 [142] but only the predicted slight reduction in CDKN1A expression
(1.4-fold) was observed in NuKO cells. Thus, there is no clear evidence to support the relief of
HINT1 repression of transcription factors as a cause of Ap4A-mediated differential gene
expression in KBM-7 cells.
Purinoceptors. Some Ap4A-mediated transcriptional changes could also involve external-
ization of Ap4A into the growth medium by exocytosis or from damaged or necrotic cells. This
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Ap4A could then act through cell-surface purinoceptors to modulate known signaling path-
ways leading to changes in gene expression [143]. All known P2 receptor subtypes except
P2X2, P2X3, P2X6, P2Y4, P2Y12 and P2Y13 were found to be expressed in KBM-7 cells with
P2X1, P2X7 and P2Y8 showing slight but significant up-regulation (1.3–2.3-fold) in NuKO
cells (S2 and S3 Tables). Several of these are known to be activated by Ap4A [144]; however,
measurement of Ap4A in the cell-free growth medium showed that there was actually less in
the medium taken from NuKO cells (0.11 ± 0.01 pmol/106 cells, n = 3) than in that from KBM-
7 cells (0.28 ± 0.07 pmol/106 cells, n = 3), possibly due to the 5.5-fold up-regulation of the cell
surface phosphodiesterase ENPP1, which is known to hydrolyze extracellular diadenosine
polyphosphates [3]. Thus, an increased autocrine signaling effect of Ap4A seems unlikely.
Chromatin remodeling. PARP1 and PARP2 are known to be intimately involved in chro-
matin (de)condensation and epigenetic marking through ADP-ribosylation of histones and
chromatin remodeling enzymes and via interaction with numerous transcription factors, and
this has profound effects on gene expression [145]. Ap4A can effectively compete with histones
as an ADP-ribose acceptor resulting in the synthesis of ADPR-Ap4A species [17, 146, 147] and
so an elevated level of Ap4A could conceivably regulate, or just interfere with, these processes
leading to changes in gene regulation. However, the lack of effect on the expression of the
selected gene set studied by qRT-PCR after inhibition of PARP1 and PARP2 would argue
against a major role for PARPs. Nevertheless, the expression of a large number of histone gene
variants is affected by NUDT2 disruption, the majority being down-regulated, while changes in
the expression of several lysine-specific demethylases (KDMs), histone deactylases (HDACs)
and DNA (cytosine-5)-methyltransferases (DNMTs), several of which are also ADP-ribosyla-
tion targets, is also evident (S3 Table). Hence, Ap4A-mediated chromatin remodelling by some
unknown mechanism could still be considered as a potential source of differential gene
expression.
Protein kinases and other ATP-dependent factors. By virtue of its structural similarity to
ATP, Ap4A might regulate transcription by inhibition of protein kinases, of which there are
over 500 in the human genome [148]. Ap4A has been shown to inhibit v-Src [26], casein kinase
II [27] and protein kinase C [28]. These and many other protein kinases, some of which might
be particularly sensitive to Ap4A, are known to regulate transcription factor activity directly or
indirectly and several examples of potential targets feature in Figs 4–6. In the absence of evi-
dence strongly favoring alternative possibilities, protein kinases and other ATP-dependent reg-
ulatory factors such as phosphoinositide kinases, chaperones and ABC transporters must be
regarded as likely targets for Ap4A that will require future investigation.
Transcript stability. An alternative mechanism whereby increased Ap4A could have a
major effect on the transcriptome is through inhibition of RNA binding by the nudix protein
NUDT21 (CFIm25, CPSF5), the 25 kDa component of the cleavage factor Im complex
involved in pre-mRNA 30-end processing. Ap4A binds to the same site as RNA with a Kd of
2.4 μM and so might be expected to affect 30-end processing and the half-lives of certain
mRNAs [35, 149]. Knockdown of NUDT21 in glioblastoma cells results in shortened 30-UTRs
in 1450 transcripts and an increase in cell proliferation [150]. Of these 1450 transcripts, the
steady-state levels of 928 were significantly increased and 28 were decreased. However, a com-
parison between the transcripts affected after NUDT21 knockdown in glioblastoma cells and
those up- and down-regulated in NuKO cells revealed no overlap between the down-regulated
genes and only 1 overlap in the top 250 up-regulated genes. Therefore, despite the differences
in cell lines, it seems unlikely that NUDT21 is an important target for the increased Ap4A in
NuKO cells.
Alternative substrates or effects of NUDT2 disruption. Other in vitro substrates for
NUDT2 whose levels might be affected by its loss include Ap5A, Ap6A, other
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homodinucleoside polyphosphates with four or more phosphoryl groups, e.g. diguanosine tet-
raphosphate (Gp4G) [4, 5], inorganic polyphosphate [151] and phosphoribosyl pyrophosphate
[152], but there is no evidence to suggest that these are significant substrates in vivo [4]. Ap5A
and Ap6A appear to be confined to secretory granules in certain specialized cells while no spe-
cific mechanisms are known for the synthesis of Gp4G and other homodinucleoside polypho-
sphates in mammalian cells [4, 5]. Heterodinucleoside polyphosphates such as Ap4G and
Ap4U can also be synthesized by aminoacyl-tRNA synthetases and, if present, would be
detected by our luminometric assay and included as part of the ‘Ap4A’ pool, but as no unique
functions have been ascribed to these molecules they are usually considered under the heading
‘Ap4A’ [4].
Transcript stability could also be affected if NUDT2 were involved in mRNA decapping. So
far, two related nudix family proteins, DCP2 (NUDT20) and NUDT16, have been shown to
participate in mRNA decapping in vivo [153]. However, a further six nudix proteins, including
NUDT2, have varying degrees of decapping activity in vitro on both monomethylated and
unmethylated capped RNAs [154]. Although there is currently no evidence supporting
NUDT2-mediated decapping in vivo, this possibility cannot be discounted. Additionally, by
virtue of its structural similarity to caps, elevated Ap4A could conceivably inhibit decapping by
DCP2 and NUDT16. In both cases, this would most likely lead to prolonged half-lives of
mRNA subsets and might therefore contribute to the up-regulation of certain genes.
Finally, loss of NUDT2 could have consequences through the loss of interaction with any
binding partner. NUDT2 may have a significant nuclear location [155, 156] and has been docu-
mented to bind to the replicative helicase component MCM6 [157]. While this may in some
way be related to the inhibition of replication initiation by Ap4A [17], it is not clear how loss of
this interaction would have the profound effect on transcription observed in NuKO cells.
NUDT2 has also been reported to bind to unliganded estrogen receptor beta (ESR2) in the
cytosol [158]. This is interesting given the reported repression of NUDT2 expression by estra-
diol [78, 159]. However, no significant expression of ESR2 was detected in KBM-7 cells (S2
Table and [38]) and so it seems unlikely that the effects of NUDT2 disruption involve ESR2-
mediated gene expression. Thus, aside from a theoretical effect of NUDT2 loss on mRNA dec-
apping, it seems reasonable to conclude that most of the transcriptional effects reported here
are caused by an increased level of its major substrate, Ap4A. We did attempt to answer this
question directly by expression of the Escherichia coli ApaH gene in NuKO cells. ApaH encodes
a symmetrically-cleaving Ap4A hydrolase that it structurally unrelated to NUDT2 [160] and in
so doing we hoped to reduce Ap4A to normal levels in a NUDT2-negative background. How-
ever, ApaH expression proved to be toxic to the cells, possibly because ApaH may also have
protein phosphatase activity [161].
Discussion
Despite being known since the 1960s, Ap4A has never commanded the attention that has been
bestowed on other low-molecular-weight regulators such as cyclic nucleotides and inositol
phosphates. Two competing schools of thought have arisen, one suggesting that Ap4A is a
physiologically important regulator whose level is finely tuned by the NUDT2 Ap4A hydrolase,
and the other that it is an unavoidable, non-functional by-product of several enzyme activities
and that NUDT2 exists simply to eliminate it, lest it cause molecular mayhem by interfering
with essential, adenine nucleotide-dependent metabolic and regulatory pathways [4]. The data
presented here clearly demonstrate that increases in intracellular Ap4A by disruption of a single
gene lead to significant changes to the transcriptional program. While some of the observed
changes in gene expression may indeed be adventitious due to an unregulated and sustained
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high level of Ap4A, the specific down-regulation of gene sets involved in the interferon, inflam-
matory and innate immune responses and in cancer promotion support the view that Ap4A is
indeed a biologically relevant regulator. Assuming that Ap4A has more than one intracellular
target, it is likely that different gene sets will respond to different levels of Ap4A resulting from
the regulation of NUDT2 activity, translation or transcription in vivo in response to different
factors, and so not all the effects observed in NuKO cells will necessarily occur at the same
time. Identification of these targets and the gene networks under their control is a priority for
future work.
Taking the positive view that Ap4A is a bona fide regulator, what conclusions can be drawn
about its principal intracellular role(s)? Rapid suppression of interferon responses after activa-
tion of the initial signal transduction pathways is an essential part of the overall immune
response to pathogens to avoid the potential toxicity of the many anti-viral, pro-apoptotic, and
anti-proliferative proteins that are induced. Therefore, the NuKO phenotype may reflect the
activation of these feedback mechanisms. Alternatively, components from infecting pathogens
such as proteins or 50-ppp RNAs may actively cause the increased intracellular Ap4A by inhib-
iting NUDT2 in order to down-regulate the immune responses. Poliovirus infection is known
to cause a slight (2-fold) increase in Ap4A [162] while the SARS coronavirus protein 7a physi-
cally interacts with NUDT2, although the effect of this on the level of Ap4A is not known
[163]. Recently, it has been shown that the viral-induced mediator of the interferon response,
cyclic GAMP, can be transferred from cell to cell inside newly-formed virions, and it has been
speculated that this is a protective, host-regulated mechanism to rapidly establish an antiviral
state in newly infected cells [164, 165]. It is equally interesting to speculate that viruses may
also package Ap4A into new virions to counteract this. With regard to bacterial pathogens, the
two types of bacterial Ap4A hydrolase, the asymmetrically-cleaving NUDT2 homologue RppH
(also known as YgdP or IalA) and the unrelated symmetrically-cleaving ApaH, have been clas-
sified as invasion proteins and are required for optimal survival of bacteria during cellular inva-
sion [166–169]. They may help to prevent high host cell Ap4A induced by infection-associated
stress from inhibiting essential bacterial functions.
The down-regulation of tryptophan catabolism by Ap4A offers a possible explanation as to
why, of all the aminoacyl-tRNA synthetases able to generate diadenosine oligophosphates,
mammalian tryptophanyl-tRNA synthetase (WRS) is the only one unable to synthesise Ap4A.
It can only make Ap3A [170]. WRS is expressed constitutively in all cells, but can be strongly
induced in many non-lymphoid cells, e.g. monocytes, by Type II interferons, leading to a
marked increase in Ap3A, but not Ap4A [171, 172]. It has been proposed that this induction
protects non-lymphoid cells from Trp depletion and the other effects of IDO1 expression by
ensuring that sufficient Trp is diverted into protein synthesis for survival [173]. Enhanced
WRS expression in T cells from patients with several autoimmune disorders is also believed to
protect them from Trp depletion [72]. If this increased level of WRS were also to generate a sig-
nificant amount of Ap4A, this would compromise the intended immunosuppression by down-
regulating Trp catabolism. Hence, WRS may have evolved a unique inability to make Ap4A.
This also seems to confirm the physiological relevance of Ap4A as an important signaling
molecule.
Regardless of the mechanisms where by Ap4A exerts its effects and whether these are all
physiologically relevant, the practical significance of inhibiting NUDT2 is evident. Our results
expand upon the earlier demonstration that NUDT2 promotes proliferation of breast carci-
noma cells and that NUDT2 status could be a useful prognostic marker [78]. The potential of
NUDT2 as a pleiotropic therapeutic target for cancer simultaneously affecting metastasis, inva-
sion, apoptosis, immunosuppression and inflammation certainly warrants further investigation
and validation in different cancer cells and animal models. There are currently no known
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specific small molecule inhibitors of NUDT2; however such molecules have been described for
the related nudix hydrolase MTH1 [174, 175], suggesting that specific inhibition of NUDT2
may be feasible. It could also be targeted with biotherapeutics. The extent to which the changes
in the expression of other genes and pathways brought about by NUDT2 disruption might mili-
tate against its value as a target will only be determined by further investigation.
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